Researchers found that newer medications appear to keep patients on therapy longer, while side effects remain a major reason for discontinuation
Long-chain acylcarnitines are essential intermediates in the carnitine shuttle, and their pathological buildup is associated with mitochondrial dysfunction, oxidative stress, and inflammationkey processes in DKD progression [33, 39, 49,50,51,52]
pharmaceutical landscape, GLP-1 medications have surged to blockbuster status, driven by soaring demand for both diabetes management and weight loss solutions
(97), have developed SLNs co-loaded with dopamine for intranasal administration, which offers a multifunctional approach to PD treatment
Folate therapy and in-stent restenosis after coronary stenting
The two companies brought in a combined $41 billion from the treatments last year